Editor’s Note: The HealthWell Foundation is the founding sponsor of Real World Health Care. This Real World Health Care column is not like others I’ve written. But then again, this year is not like any other we’ve lived through. I would typically use this end-of-year column to thank you for…more.
- RWHC Home
- About RWHC
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Behavioral Health
- Movement Disorders
- Big Data
- Multiple Myeloma
- CAR-T Cell Therapy
- Non-Small Cell Lung Cancer
- Nonalcoholic Steatohepatitis
- COVID 19
- Pain Management
- Hepatitis C
- Personalized Medicine
- Secondary Progressive MS
- Macular Degeneration
As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda’s Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct…more.
Over the past two decades there’s been tremendous progress in understanding how to harness the body’s immune system to fight cancer. Today, immunotherapy is a mainstay of cancer treatment. One of the most exciting areas of immunotherapy is CAR (chimeric antigen receptor) T-cell therapy. This treatment involves purifying a special…more.
Last year, the Multiple Myeloma Research Foundation (MMRF) launched a new, three-year strategic plan to help transform how multiple myeloma is treated and ultimately cured. One of the plan’s three strategic pillars focuses on immunotherapy, including chimeric antigen receptor T-cell (CAR-T) therapy. Real World Health Care spoke with the MMRF’s…more.
Editor’s Note: This week, Real World Health Care shares an inspirational story of a woman who was diagnosed with lymphoma and received treatment with CAR T-cell therapy. “CAR-T Cell Therapy Gave Me My Life Back” is reprinted with permission from the Association of Community Cancer Centers. Updated in April 2020,…more.
CAR T-cell therapy (CAR-T) has emerged as a highly innovative and promising option for patients with cancer. Until recently, the use of CAR-T has been restricted to small clinical trials, primarily with patients with advanced blood cancers. These trials often are conducted at large, academic medical centers in major metropolitan…more.
Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.
Editor’s Note: This article originally appeared in Biotech Primer Weekly. For more of the science behind the headlines, please subscribe. Multiple myeloma is a cancer formed by a type of white blood cell called a plasma cell. These cells are the antibody-producing cells of our immune system and play a…more.